Adult linear IgA disease associated with an erythema multiforme-like drug reaction.
D002435:Cefamandole / Q000009:adverse effects / Q000031:analogs & derivatives*; D003937:Diagnosis, Differential; D003875:Drug Eruptions / Q000175:diagnosis / Q000209:etiology* / Q000276:immunology; D004892:Erythema Multiforme / Q000175:diagnosis* / Q000473:pathology; D005260:Female; D005455:Fluorescent Antibody Technique; D006801:Humans; D007070:Immunoglobulin A / Q000032:analysis*; D008875:Middle Aged; D012867:Skin / Q000276:immunology / Q000473:pathology; D012872:Skin Diseases, Vesiculobullous / Q000175:diagnosis* / Q000473:pathology
D007070:Immunoglobulin A; D002435:Cefamandole; C012810:cefamandole nafate